Description
PT-141 (Bremelanotide) 10mg — Product Identity and Format
PT-141 (Bremelanotide) 10mg is a research-grade lyophilised preparation of bremelanotide, a cyclic synthetic melanocortin analogue. PT-141 has the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH, where the cyclic structure is formed by a lactam bridge between the Asp and Lys side chains. The C-terminal modification is a hydroxyl group (OH), which distinguishes PT-141 from Melanotan II (MT2), which has a C-terminal amide (NH₂). Each vial supplied by Core Research contains 10mg of PT-141, verified by RP-HPLC to ≥99.0% purity with identity confirmed by ESI-MS. Batch-specific analytical documentation is available through the Core Research CoA Portal.
Regulatory Boundary — Research Material vs Authorised Medicinal Product
Bremelanotide is the active substance in Vyleesi® (Palatin Technologies / AMAG Pharmaceuticals), an FDA-approved medicinal product authorised in the United States for hypoactive sexual desire disorder (HSDD) in premenopausal women. This FDA approval applies to the authorised medicinal product Vyleesi® and its specific formulation, not to the Core Research RUO vial.
The existence of an FDA-approved bremelanotide medicine does not change the research-only status of this product. Researchers should be aware of the regulatory distinction between the authorised medicinal product and the RUO research material when documenting their work.
Compound Identity
| Attribute | Value | Notes |
|---|---|---|
| Common Names | PT-141, Bremelanotide | Cyclic melanocortin analogue; distinct from MT2 (C-terminal amide) and MT1 (linear) |
| Sequence | Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH | 7 amino acids; cyclic via Asp-Lys lactam bridge; N-terminal acetyl-Nle; C-terminal hydroxyl (OH) — not amide |
| CAS Number | 189691-06-3 | Bremelanotide (free acid); verify salt form against batch CoA |
| Molecular Formula | C50H68N14O10 | Free acid (cyclic) |
| Molecular Weight | 1,025.2 Da | Free acid (average) |
| Salt Form | Acetate | Research-grade lyophilised preparation; verify against batch CoA |
| Distinction from MT2 | C-terminal OH (PT-141) vs C-terminal NH₂ (MT2) | Same cyclic core sequence; different C-terminal modification; distinct pharmacological profiles |
| Physical Form | White lyophilised powder | Research-grade preparation |
Analytical Specification
| Test Parameter | Method | Specification |
|---|---|---|
| Purity (RP-HPLC) | C18 column, UV 220 nm | ≥99.0% |
| Identity (ESI-MS) | Electrospray ionisation MS | ±0.1 Da of theoretical MW (1,026.2 Da [M+H]⁺) |
| Endotoxin (LAL) | Kinetic turbidimetric LAL | <1.0 EU/mg |
| Appearance | Visual inspection | White lyophilised powder |
Sterility note: This product is described as a lyophilised research-grade preparation. Sterility-release testing data, if applicable, is documented on the batch-specific CoA. Researchers should verify the sterility status against the batch CoA before use in sterility-sensitive assay systems.
Storage and Transport
| Condition | Specification |
|---|---|
| Long-Term Storage | −20°C, protected from light and moisture |
| Stability Period | Stated on the batch-specific CoA |
| Transit | Ambient; cold-chain packaging included for applicable orders |
Batch Documentation
Every batch of PT-141 10mg dispatched by Core Research is accompanied by a batch-specific Certificate of Analysis. CoA documents are available via the Certificate of Analysis Portal.
Frequently Asked Questions
What is the difference between PT-141 and MT2?
PT-141 (bremelanotide) and MT2 (melanotan II) share the same cyclic core sequence (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]) but differ in the C-terminal modification: PT-141 has a C-terminal hydroxyl group (OH); MT2 has a C-terminal amide (NH₂). This structural difference results in distinct pharmacological profiles. PT-141 was originally identified as a metabolite of MT2 formed by hydrolysis of the C-terminal amide in vivo.
Where can I access the Certificate of Analysis?
Batch-specific CoA documents are available via the Core Research CoA Portal.
Research Use Only. PT-141 (Bremelanotide) 10mg is supplied by Core Research exclusively for in vitro laboratory research. Not for human or veterinary use. Not the authorised medicinal product Vyleesi®. No dosing, administration, sexual-function, HSDD, erectile-function, or clinical guidance is provided.
Research context
The published literature on this material is summarised in the laboratory guides linked below. This record describes the material as supplied: identity, format, analytics, storage and documentation. It does not describe effects, and none should be inferred from the catalogue category.
For Research Use Only
PT-141 (Bremelanotide) is supplied exclusively for in vitro laboratory research. Not for human or veterinary use. No dosing, reconstitution, or administration guidance is provided. This product is not the authorised medicinal product Vyleesi®.
